1	COVID 10 and definitions, discussive testing emitaria, and summillance serves the nondemie's 25
1	COVID-19 case definitions, diagnostic testing criteria, and surveillance across the pandemic's 25
2	highest burden countries
3	
4	Amitabh B. Suthar ^{1*} , Sara Schubert ^{1*} , Julie Garon ¹ , Alexia Couture ¹ ,
5	Amy M. Brown ² , Sana Charania ¹
6	
7	¹ International Task Force, Novel Coronavirus (COVID-19) Response, Centers for Disease
8	Control and Prevention, Atlanta, GA, U.S.A
9	² Data, Analytics, and Visualization Task Force, Novel Coronavirus (COVID-19) Response,
10	Centers for Disease Control and Prevention, Atlanta, GA, U.S.A
11	* These authors contributed equally to this work
12	
13	Corresponding author: Dr. Amitabh Bipin Suthar, icf4@cdc.gov
14	
15	Disclaimer: The findings and conclusions in this report are those of the authors and do not
16	necessarily represent the official position of the Centers for Disease Control and Prevention.
17	
18	Running title: Global COVID-19 surveillance
19	Word Count: 3,144
20	References: 73
21	Funding: None

22 Abstract (250 words)

23

Objective: We compared suspect, probable, and confirmed case definitions, as well as diagnostic testing criteria, used in the COVID-19 pandemic's 25 highest burden countries to aid interpretation of global and national surveillance data.

27

Methods: We identified the COVID-19 pandemic's 25 countries with the highest disease burden based on the number of cumulative reported cases to the World Health Organization (WHO) as of 1 October 2020. We searched official websites of these countries for suspect, probable, and confirmed case definitions. Given that confirmation of COVID-19 usually requires diagnostic testing, we also searched for diagnostic testing eligibility criteria in these countries. Extracted case definitions and testing criteria were managed in a database and analyzed in Microsoft Excel.

34

35 Findings: We identified suspect, probable, and confirmed case definitions in 96%, 64%, and 36 100% of countries, respectively. Testing criteria were identified in 100% of countries. 56% of 37 identified countries followed WHO recommendations for using a combination of clinical and 38 epidemiological criteria as part of the suspect case definition. 75% of identified countries 39 followed WHO recommendations on using clinical, epidemiological, and diagnostic criteria for 40 probable cases. 72% of countries followed WHO recommendations on using PCR testing for 41 confirming a case of COVID-19. Finally, 64% of countries used testing eligibility criteria at least 42 as permissive as WHO.

43

44 Conclusion: There is marked heterogeneity in who is eligible for testing in countries and how
45 countries define a case of COVID-19. This affects the ability to compare burden, transmission,
46 and response impact estimates derived from case surveillance data across countries.

47 Background

48 Novel infectious pathogens can pose major challenges to global health and security. Tracking the 49 geography, demographics, and suspected mode of transmission of these pathogens using a 50 standardized case definition remains the foundation for surveillance. Severe acute respiratory 51 syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), was first characterized in December 2019.¹ By January 2020, the first national case 52 definition was developed² and the World Health Organization (WHO) declared novel 53 coronavirus disease 2019 a public health emergency of international concern.³ WHO's interim 54 55 guidance for global COVID-19 surveillance, released on 31 January 2020, included a hierarchy of confirmed, probable and suspect case definitions.⁴ This guidance encouraged the use of all 56 57 available clinical, epidemiological and laboratory evidence for case classification purposes. In 58 addition, it noted that countries may need to adapt the case definitions to their unique 59 epidemiological situation. Recommendations for testing suspected cases and widespread testing were included based on transmission intensity, number of cases, and available resources. 60

61

62 Both WHO and national case definitions have evolved over time with growing knowledge about COVID-19 etiology and the myriad of ways the disease manifests after infection.⁴⁻⁶ Early on, 63 64 surveillance emphasized a travel history to Wuhan, China, where the initial outbreak occurred, 65 and a narrowly defined set of symptoms. However, the virus rapidly spread to other provinces in 66 China and then internationally, and reports of patients who either experienced new symptoms or remained asymptomatic increased.⁷ Confirming a COVID-19 case relies on diagnostic testing 67 and, therefore, testing capacity has played an important role in countries' COVID-19 68 69 surveillance efforts. The types of tests available have expanded to include molecular and antigen 70 tests to detect the presence of the SARS-CoV-2 virus and serology tests to detect antibodies produced from previous SARS-CoV-2 infection.^{8,9} However, the availability of these tests and 71 72 the resources needed to collect, handle, and process clinical specimens have varied widely across nations.¹⁰ Shortages of test kits and reagents and lack of laboratory capacity have forced many 73 locales to make tough decisions about policies for testing.¹¹ 74

75

76 Differences in case definitions pose a challenge not only to detect the true number of cases 77 within countries, but also to understand the global burden of disease and adequately respond to

78 pandemics. While global guidelines have been developed for testing eligibility criteria and case 79 definitions, these are usually reviewed at a national level and are subject to adaptation based on 80 laboratory and health system considerations. Earlier evaluations of global COVID-19 case 81 definitions do not reflect the latest changes to national case definitions and test eligibility criteria and do not target the full range of countries with the highest burden of disease.^{12–14} In this study. 82 83 we analyze (1) national COVID-19 case definitions from the 25 countries with the largest 84 number of reported COVID-19 cases as of 1 October 2020 (collectively representing 85 approximately 85% of the global cases at that time) and (2) specific criteria used to determine 86 eligibility for SARS-CoV-2 diagnostic testing. The implications of inter-country differences on 87 ongoing efforts to understand global disease burden and control the pandemic are also discussed.

88

89 Methods

90 Design

The 25 countries with the highest burden of COVID-19 disease were identified from WHO COVID-19 cumulative case counts as of 1 October 2020.¹⁵ The surveillance case definitions and official testing policies were extracted from official government websites for the respective countries. In instances where definitions were not available on official government websites, definitions were extracted from personal communication with the U.S. Centers for Disease Control and Prevention (CDC) field staff.

97

To find these data, we searched government websites using the following key words: case definition, suspect case, confirmed case, COVID-19, case criteria, surveillance, testing criteria, guidelines, laboratory, reverse transcriptase-polymerase chain reaction (RT-PCR), and asymptomatic. All surveillance definitions and testing criteria were verified as current as of 1 January 2021. Several of the official policies were not available in English. For these documents, we used Google Translate to identify the definitions and testing policies.

104

105 Data management and analysis

106 In order to compare case definitions across countries, we classified the components of each 107 definition into three parts: (1) diagnostic components including a laboratory test or radiographic 108 imagery; (2) clinical symptoms (such as cough, fever, and Severe Acute Respiratory Infection

109 (SARI)); and (3) epidemiological criteria, including travel to a high-burden region or contact 110 with a confirmed or suspect case. For each country's testing policy, we considered individuals 111 eligible for diagnostic testing. Countries were classified as testing asymptomatic individuals 112 without any additional criteria, testing asymptomatic individuals with some epidemiological 113 criteria, such as contact with a confirmed case, or recommending testing exclusively for 114 symptomatic individuals. These analyses were based solely on diagnostic testing eligibility 115 criteria and did not consider exceptions, such as testing asymptomatic individuals prior to travel, 116 asymptomatic testing through the private sector, or local-level mass-testing. Elements of national 117 case definitions and testing criteria were compared against global norms from WHO.

118

119 Source assessment

120 To assess sources, we extracted information on their origin and timeliness. The origin was 121 categorized as a government source or personal communication while timeliness was based on 122 date of publication.

123

124 **Results**

125 Suspect case definitions

126 We identified suspect case definitions in 24 of 25 countries (96%) (Table 1 and Appendix 1). 127 Israel relies on surveillance via cell phone data; we used these epidemiological criteria from 128 Israel to create a suspect case definition. The three most common criteria included in suspect 129 case definitions were fever, cough, and labored breathing (reported in 92%, 84%, and 84% of 25 130 countries). Seven countries (28%) used "other" criteria in addition to the common criteria listed 131 in Table 1. The WHO suspected case definition includes clinical symptoms, including the three 132 most common stated above, and epidemiological criteria. Fourteen (56%) countries followed this 133 guidance broadly by including clinical and epidemiological criteria, ten (40%) countries required 134 clinical symptoms alone for the suspect case definition, while two countries (8%) also 135 incorporated diagnostic testing. The United States relies on laboratory evidence, including 136 antibody or antigen positivity, without any clinical symptoms or epidemiological criteria while 137 Colombia primarily relies on epidemiological criteria and clinical symptoms, but includes laboratory and radiological tests as part of their definition to assist with diagnoses.^{16,17} 138

140 Probable case definitions

141 We identified probable case definitions in 16 of 25 countries (64%) (Table 2 and Appendix 2). 142 The WHO probable case definition includes criteria from all three categories, diagnostic testing 143 (chest imagery), clinical symptoms, and epidemiological criteria. 12 out of 16 countries (75%) 144 were consistent with WHO and included criteria from all three categories. There was 145 heterogeneity in the number of required criteria across countries. The three most common criteria 146 included in probable case definitions were fever, labored breathing, and confirmed contact with a 147 probable or confirmed case (reported in 94%, 88%, and 81% of the 16 identified countries, 148 respectively). Fourteen (88%) countries included some type of diagnostic testing for the probable 149 case definition, fifteen (94%) included clinical symptoms in their definitions, and fourteen (88%) 150 included epidemiological criteria.

151

152 *Confirmed case definitions*

153 We identified confirmed case definitions in all 25 countries (100%) (Table 3 and Appendix 3). 154 All confirmed case definitions required some type of diagnostic testing. Eighteen (72%) 155 countries were consistent with WHO's recommendations and specified RT-PCR tests in their 156 case definition. Of these countries, ten (40%) also included antigen or antibody tests in their 157 definition. Seven countries (28%) did not specify a type of diagnostic test. Seven countries 158 (28%) include reference to their suspect case definition within their confirmed case definition. Of 159 these, three countries (Mexico, Saudi Arabia, and Turkey) require that an individual meet the 160 suspect case definition in addition to diagnostic testing criteria. In addition to confirming cases 161 based on diagnostic testing, six (24%) countries confirmed cases exclusively on loss of taste or 162 smell (anosmia or ageusia). Overall, eight countries (32%) included clinical symptoms as part of 163 their confirmed case definition.

164

165 Testing eligibility criteria

We identified testing criteria in all 25 countries (100%) (Appendix 4). Eight (32%) of countries had no symptom requirements for testing, eight (32%) had no symptom requirements for testing but required epidemiological criteria, i.e., exposure to a confirmed or probable case, and nine (36%) countries required symptoms. Of the eight countries requiring epidemiological criteria, five (63%) also allowed asymptomatic testing for a healthcare worker (Appendix 4). Policies

171 from Saudi Arabia and the United Kingdom specified not to test asymptomatic individuals but 172 included an exception for healthcare employees (Appendix 4). WHO recommends testing 173 asymptomatic individuals who have had contact with a confirmed case; 64% of countries used 174 eligibility criteria at least as permissive as WHO.

175

176 *Source assessment*

177 92% of case definitions were found on official government websites and 72% were published or 178 included in documents published after the most recent WHO definition was published (7 August 179 2020) (Table 4). Two countries (India and Pakistan) utilized the previous WHO definition (dated 180 March 2020). We were unable to confirm that these countries updated their definition based on 181 the newest WHO definitions. We were unable to locate definitions on Israel, Iraq, and Iran's 182 government websites. In these countries, we obtained definitions from personnel involved in the 183 respective country's COVID-19 response. 23 of 25 countries (92%) had an official government 184 source for diagnostic testing criteria. Iraq and Iran testing criteria were obtained via personal 185 communication. 88% of testing criteria were published after 1 September 2020. The policies for 186 Philippines, Brazil, and Pakistan were updated in July and August 2020.

187

188 **Discussion**

189 A consistent statement across all iterations of WHO's global COVID-19 surveillance guidance is that countries may need to adapt the case definitions to their specific circumstances.^{4-6,18} 190 191 Beginning with the 20 March 2020 version, WHO also encouraged countries to publish their adapted versions online and in periodic situation reports.^{5,6} Nearly all countries (92%) in this 192 193 analysis indeed chose to deviate from WHO's case definitions in some manner and 92% of 194 countries posted their case definition on an official government website. Suspect and confirmed 195 case classifications were found for nearly all countries, but over a third (36%) excluded the 196 probable case classification. In addition, substantial variation was observed among testing 197 criteria used across the national case definitions. While WHO reserved the use of laboratory 198 testing for confirmed cases only, two countries (8%) included laboratory evidence for suspect 199 cases, 14 countries (88%) for probable cases, and nearly a third (32%) included non-laboratory 200 criteria for confirmed cases. Laboratory evidence in some countries was not restricted to RT-201 PCR, but rather included increasingly available antigen and antibody tests. Lastly, testing

eligibility criteria also differed widely with many countries either excluding asymptomatic
individuals from routine testing (36%) or only including them under certain conditions (32%).

204

205 Differences in case definitions and testing eligibility can have important implications on efforts 206 to monitor disease trends and understand the impact of vaccine scale-up efforts across countries 207 and over different time periods. As knowledge of a novel disease increases, the sensitivity and 208 specificity of the case definition changes over time, ultimately impacting the number of cases identified.¹⁹ For example, in 2003 during the earlier SARS epidemic, the Netherlands had several 209 210 iterations of case definitions that diverged from the prevailing WHO case definition, which was 211 more sensitive and less specific in comparison. When all cases were reevaluated, 21 cases were 212 classified as suspect and two as probable using the latest WHO case definition as opposed to just nine suspect and zero probable cases using the Dutch case definitions.²⁰ As the COVID-19 213 214 pandemic emerged in China, a 12 February 2020 case definition change to include clinically diagnosed mild cases resulted in identification of more than 15,000 cases in a single day.²¹ A 215 216 study of China's successive case definitions, each with gradually increasing sensitivity, also vielded higher detection of cases.¹⁴ From 15 January to 3 March 2020, China's National Health 217 218 Commission used seven versions of the case definition for COVID-19, estimated to increase the 219 proportion of cases being detected by seven times after the first change, three times from change 220 two to four, and four times after the fifth change. The authors estimated that if the fifth version of 221 the case definition had been applied throughout the outbreak, there would have been 4.2 times 222 more confirmed cases identified in China by 20 February 2020 (232,000 compared to 55,508). 223 These data suggest that use of less sensitive case definitions can underestimate the burden of 224 COVID-19. Changes in case definitions may need to be considered while analyzing an epidemic 225 curve for COVID-19 or other novel diseases.

226

The wide variation we found in suspect and probable case criteria – and the complete omission of the probable case classification in some nations – is of particular interest. When test results are still pending or tests are unavailable, inclusion of suspected and probable cases allows for early isolation and treatment of these cases.⁷ In addition, in its 7 August 2020 guidance, WHO requested that countries include counts of probable cases along with confirmed cases in weekly

aggregate reports.⁶ WHO indicated that suspected and confirmed case definitions were revised to reflect increased knowledge of the clinical spectrum of COVID-19 signs and symptoms, especially the most common and predictive. These updates were important to informing global and national surveillance because some symptoms have been found to have limited predictive value for surveillance purposes despite their frequent inclusion in case identification procedures.^{22–25}

239 WHO case definition guidance does not explicitly state the type of test for diagnostic 240 confirmatory testing but references the laboratory guidance that recommends nucleic acid amplification tests (NAAT), such RT-PCR assays.²⁶ Many counties may not have considered the 241 242 laboratory guidance and used the WHO confirmed case definition verbatim. Indeed, we found 243 that seven of the high burden countries did not specify the type of test to be used in confirmatory 244 testing. Results indicating some countries' use of alternatives to NAAT as laboratory evidence is 245 another important finding. Antigen tests, particularly point of care tests, have been promoted as an important tool for early detection and to prevent asymptomatic spread.⁹ However, their 246 sensitivity is generally lower than NAAT leading to false negatives.²⁷ Antibody tests have 247 typically been recommended as a surveillance assay rather than a standalone diagnostic tool.^{11,28} 248 249 Despite the limitations of NAAT alternatives, they are increasingly available in many areas and 250 have important benefits, such as lower overall cost, simplified logistics and supply chain 251 management, and faster turnaround of results for rapid versions that may explain their integration 252 in some national confirmed case definitions.

253

254 WHO's public health surveillance guidance also includes recommendations for laboratory testing 255 of all suspect and probable cases but acknowledges that testing priorities would be dependent on 256 intensity of transmission, the number of cases, and laboratory capacity. Therefore, guidance was 257 also developed on testing asymptomatic and mildly symptomatic individuals.^{6,26} National 258 differences in testing eligibility criteria may also reflect resource limitations and differences in national health insurance coverage of tests.¹² A number of testing strategies proposed to target 259 260 segments of the population believed to be at greatest risk of exposure to SARS-CoV-2. For 261 example, some have proposed testing all symptomatic individuals and asymptomatic individuals

²³⁸

with known or suspected contact with COVID-19 case for optimal NAAT testing.^{9,26} Testing 262 263 asymptomatic individuals without an exposure was suggested if results would impact isolation, quarantine, personal protective equipment usage decisions, surgery eligibility, or inform 264 administration of immunosuppressive therapy.²⁹ In Australia, the national testing policy 265 266 emphasized defining and targeting high-risk settings, such as residential care facilities or correctional facilities for testing.³⁰ In May 2020, the European Centre for Disease Prevention and 267 268 Control expanded the pool of individuals eligible for laboratory testing, resources permitting, to 269 include asymptomatic individuals in healthcare settings and long-term care facilities, to identify potential sources of infection and protect vulnerable individuals.¹³ 270

271

272 In order to get accurate case counts, detecting both symptomatic and asymptomatic cases is 273 necessary due to the large proportion of COVID-19 cases presenting with no or mild 274 symptoms.²⁹ Inclusion of asymptomatic cases also impacts key epidemiological metrics, such as 275 incidence and the case fatality ratio. While expansive testing criteria will increase the likelihood 276 of capturing asymptomatic infections, they should be balanced against the burden for the public health system in tracing and testing these eligible individuals.³⁰ For example, broadening testing 277 278 eligibility criteria may overload the healthcare system with individuals with a low probability of 279 infection and/or disease progression. Furthermore, many settings may not have enough resources to test all eligible individuals.²⁹ Although WHO provides harmonious global testing criteria and 280 281 case definitions, our findings suggest heterogeneity in how these were adapted and that it might 282 be necessary to account for these deviations when comparing COVID-19 case trends across 283 countries.

284

There are several methodological limitations to our analysis. First, although the included studies represented approximately 85% of the reported cases globally, there may be differences in case definitions among the countries comprising the remaining 15%. Second, although we identified suspect case definitions, confirmed case definitions, and testing criteria for most countries, we only identified probable case definitions in 16. This may be due to the lack of a probable case definition or the lack of making it available in the public domain; regardless, the results of the probable case definition analyses may be less generalizable than the others. Third, since Google

292 Translate was used to translate definitions not in English, there may have been discrepancies 293 between the original policy intent and what we were able to interpret from the translation. 294 Fourth, our scope was limited to confirmed, probable and suspect case definitions; other 295 classifications, such as persons under investigation, may merit further research. Fifth, after 296 extraction and analyses were completed, additional issues relating to case surveillance have 297 emerged. These include criteria for distinguishing a new case from an existing case, i.e., reinfection cases, as well as the B.1.1.7, 1.351, and P.1 variants of COVID-19.^{16,31–33} Although 298 299 neither reinfection nor genomic sequencing were part of national case surveillance definitions, 300 reinfection surveillance may provide further information on naturally and vaccine-acquired 301 immunity whilst genomic surveillance may provide further insights on circulating strains and are 302 vital elements of comprehensive national surveillance of COVID-19. Sixth, given the large 303 number of possibilities, we chose not to list every permutation of laboratory, clinical, and 304 epidemiological criteria for the WHO and national suspect, probable, and confirmed case 305 definitions. Finally, despite our analysis of each government's policies, these policies may not be 306 implemented equally in various settings and may change over time.

307

308 Case surveillance remains the foundation for national COVID-19 surveillance and will play a 309 vital role in understanding the impact of national scale-up of vaccines and continued mitigation 310 efforts. There is marked heterogeneity in who is eligible for testing among countries and how 311 countries define a case of COVID-19. Specifically, we observed heterogeneity in elements used 312 across the suspect case definitions (heterogeneity in eligible clinical symptoms), probable case 313 definitions (heterogeneity in laboratory and diagnostic requirements), and confirmed case 314 definitions (with some countries using antigen or PCR and others only used PCR testing). 315 Importantly, testing eligibility criteria varied across countries from being restricted to populations with exposure and symptoms to not having any requirements. Collectively, these 316 317 issues suggest that efforts to compare trends of COVID-19 across countries require careful 318 interpretation.

Table 1. Suspect case definition criteria across the COVID-19 pandemic's 25 highest burden countries, current as of 1 January 2021.

320 'X' indicates the criterion was sufficient for, or a potential component of, the suspect case definition requirement(s). Full suspect case

definitions can be found in Appendix 1.

Diagnos Testing	tic J	Clinical Symptoms											1	Epidemiological Criteria				Other						
	Laboratory Evidence [*]	Cough	Fever	SARI***	Labored Breathing	Headache	Muscle Pain	throat / Odynopha	Pain / Chest Congestio	nose / Nasal Congestio	Loss of Taste or	Diarrhea	Nausea / Vomiting	Joint Pain	Chills	Rash	SPO ₂ Level****	Conjunctiv itis	Fatigue / Weakness	Travel History	Require Hospitaliz	Confirmed Contact	Health Care	Diagnostic /Clinical/E
WHO Definition † (reference)		X	X	X	X	X	X	X		X		X	X						X	X	X		X	X
Argentina		Х	Х	Х	Х	Х	Х	Х			Х	Х	Х									Х	Х	Х
Bangladesh †		Х	Х	Х	Х	Х	Х	Х		Х		Х	Х						Х	Х	Х		Х	Х
Brazil		Х	Х	Х	Х	Х		Х		Х	Х	Х			Х		Х							Xç
Chile		Х	Х	Х	Х	Х	Х	Х	Х		Х	Х			Х						Х			e c
Colombia	Х	Х	Х		Х	Х	Х	Х		Х	Х	Х	Х	Х		Х	Х	Х	Х	Х		Х	Х	X
France ^{‡*}		Х	Х		Х	Х	Х				Х	Х	Х		Х				Х					er
Germany‡*		Х	Х		Х	Х	Х				Х	Х	Х		Х				Х					C C
India ††		Х	Х	Х	Х			1		1		1				-				Х	Х	Х		Ē
Indonesia			Х	Х	Х			Х		Х										Х	Х	Х		
Iran			Х	Х						-		-	Х			-				Х				ens
Iraq†		Х	Х	Х	Х	Х	Х	Х		Х		Х	Х			-			Х	Х	Х		Х	X ^{õõ}
Israel**																				Х		Х		
Italy ^{‡*}		Х	Х	1	Х	Х	Х			-	Х	Х	Х		Х	-			Х					
Mexico		Х	Х		Х	Х	Х		Х	Х	Х			Х	Х			Х	Х					
Pakistan ++		Х	Х	Х	Х															Х	Х	Х		
Peru		Х	Х	Х	Х	Х				Х		-				-								
Philippines †		Х	Х	Х	Х	Х	Х	Х		Х		Х	Х						Х	Х	Х		Х	Х
Russia		Х	Х	1	Х		Х	Х	Х	Х	Х	Х	Х			Х	Х	Х	Х					
Saudi Arabia		Х	Х	Х	Х	Х		Х		Х	Х	Х	Х								Х	Х	Х	Х
South Africa		Х	Х	Х	Х		Х	Х			Х	Х							Х			Х		
Spain		Х	Х	Х	Х	Х	Х	Х	Х		Х	Х												
Turkey		Х	Х	Х	Х	Х	Х				Х	Х								Х	Х	Х		
Ukraine		Х	Х	Х	Х															Х	Х	Х		
United Kinadom*		Х	Х								Х													

USA	Х																1							
Total	2	21	23	16	21	15	14	12	4	10	14	15	11	2	6	2	3	3	10	11	10	10	6	7
countries																								
including																								
criterion																								
% of	8%	84%	92	64	84	60%	56%	48	16	40	56	60	44	8%	24	8%	12	12	40%	44%	40	40%	24	28%
countries***			%	%	%			%	%	%	%	%	%		%		%	%			%		%	

* These countries consider these definitions as "Possible" not "Suspected" cases; because of the comparability between possible and suspect, we treated these definitions as a suspect definition **Israel does not have official surveillance case definitions; individuals are considered suspect based on contact with confirmed cases determined by digital surveillance of cellphones

***Refer to Suspected Case Definition for applicable country (Appendix 1)

****Severe acute respiratory infection

*****Blood oxygen saturation levels

†World Health Organization definition (Updated August 2020) ††World Health Organization definition (Updated March 2020)

‡ European Centres for Disease Control and Prevention Definition

Table 2. Probable case definition criteria across the COVID-19 pandemic's 25 highest burden countries, current as of 1 January 2021.

324 'X' indicates the criterion was sufficient for, or a potential component of, the probable case definition requirement(s). Full probable

325 case definitions can be found in Appendix 2.

	1	Diagi Tes	nostic sting									ę	Clinical Symptom	IS								Epi	demiolo Criteria	gical 1	Other
	Inconclusive Test	Antigen Test	Antibody Test	Radiographic Imagery	Cough	Fever	SARI****	Labored Breathing	Headache	Muscle Pain	Sore throat / Odynophagia	Chest Pain / Chest	Runny nose / Nasal Congestion	Loss of Taste or smell	Diarrhea	Nausea/ Vomiting	Chills	Rash	SPO ₂ Level****	Conjunctivitis	Fatigue / Weakness	Travel History	Require Hospitalization	Confirmed Contact	Diagnostic/ Clinical/ EPI***
WHO Definition (Reference)				x	X	x	x	x	x	x	x		x	X	x	x					x	x	x	x	x
Argentina																									
Bangladesh†				Х	Х	Х	Х	Х	Х	Х	Х		Х	Х	Х	Х					Х	Х	Х	Х	X
Brazil																									
Chile	Х	Х		Х	Х	Х	Х	Х	Х	Х	Х	Х		Х	Х		Х						Х	Х	X
Colombia	Х				Х	Х		Х	Х	Х	Х		Х	Х	Х	Х		Х	Х	Х	Х	Х		Х	
France‡				Х	Х	Х		Х						Х										Х	X
Germany‡				Х	Х	Х		Х						Х										Х	X
India ††	Х				Х	Х	Х	Х														Х	Х	Х	
Indonesia						Х	Х	Х			Х	_	Х												Х
Iran				Х		Х	X					_		Х		Х						Х		Х	Х
Iraq†				Х	X	X	Х	X	X	Х	Х		X	X	Х	Х					Х	X	Х	X	X
Israel																									
Italy‡				Х	X	Х		Х						X										X	X
Mexico																									
Pakistan ††	X				X	Х	Х	X														X	Х	X	
Peru																									
Philippines†				Х	X	X	X	X	X	X	X		X	X	Х	Х					X	X	Х	X	X
Russia					X	Х	Х	Х	Х	Х	Х	Х	Х	X				Х	Х	Х	Х	Х		X	
Saudi Arabia																									
South Africa																									
Spain	X			Х	Х	Х	X	X	Х	Х	X	Х		Х	Х										

Turkey																									
Likraine	X						_																		
United		-				-	<u> </u>	-		-		-		-		-		-		-		-		-	
Kingdom																									
USA		Х		X	X	Х	X	X	x	Х	X		X	X	X	X	X				X			X	X
Country	6	2	0	10	13	15	11	14	8	8	9	3	7	12	7	6	2	2	2	2	6	8	6	13	10
Totals	Ŭ	-	ľ	10	10					Ŭ		Ŭ				Ŭ	-	-	-	-	Ū	Ŭ	Ŭ	10	10
% of	38	13	0	63	81%	94	69	88	50	50	56	19	44%	75	44	38	13	13	13	13	38	50	38%	81	63%
countries*	%	%	%	%		%	%	%	%	%	%	%		%	%	%	%	%	%	%	%	%		%	
***Refer to P	robable C	ase De	finitio	n for ap	plicable	countr	y (App	endix 2)																
**** Severe a	cute resp	iratory	infecti	on																					
*****Blood ox	*****Blood oxygen saturation levels																								
†World Healt	tWorld Health Organization definition (Updated August 2020)																								
††World Hea	Ith Organ	ization	defini	tion (Up	odated N	/arch 2	2020)																		
+ Europeen (Controo fo			ontrol of	nd Drow	ontion I	Dofinitio	n																	

‡ European Centres for Disease Control and Prevention Definition
 *Denominator is 16 countries with probable case definition

- 327 **Table 3.** Confirmed case definition criteria across the COVID-19 pandemic's 25 highest burden countries, current as of 1 January
- 328 2021. 'X' indicates the criterion was sufficient for, or a potential component of, the confirmed case definition requirement(s). Full
- 329 confirmed case definitions can be found in Appendix 3.

			Diagnostic Testing				\$	Clinical Symptoms	5		Ep	cal	Other*	
	PCR Test	Antigen Test	Antibody Test	Positive Test (non- specified)	Radiographic Imagery	Meet Suspect Case Definition	Cough	Fever	SARI***	Loss of taste or smell	Travel History	Require Hospitalizatio n	Confirmed Contact	Diagnostic/ Clinical/ EPI
WHO Definition (Reference)	X													
Argentina	Х	Х				Х	Х	Х		Х			Х	Х
Bangladesh†	Х													
Brazil	Х	Х	Х		Х				Х	Х			Х	Х
Chile	Х					Х				Х		Х		
Colombia	Х	Х												
France‡	Х	Х												
Germany‡	Х	Х												
India †				Х										
Indonesia	Х													
Iran				Х										
Iraq†	Х													
Israel				Х										
Italy‡	Х	Х												
Mexico				Х		Х				Х			Х	
Pakistan †				Х										
Peru	Х	Х				Х					Х	Х	Х	
Philippines†	Х	Х												
Russia	Х	Х	Х											
Saudi Arabia	Х					Х					Х	Х	Х	
South Africa	Х													
Spain	X	Х				Х				Х				
Turkey	Х					Х				Х	Х	Х	Х	
Ukraine				Х										

United Kingdom				Х										
USA	Х													
Totals	18	10	2	7	1	7	1	1	1	6	3	4	6	2
% of countries**	of countries** 72% 40% 8% 28% 4% 28% 4% 4% 4% 4% 24% 12% 16% 24% 8%												8%	
†World Health Orga	+World Health Organization definition (confirmed case definition remained the same as the March definition for the August 2020 update)													
‡ European Centre	s for Diseas	e Control an	nd Preventio	n Definition										
*Other criteria included in the Confirmed case definition														
** Denominator is 25 countries with confirmed case definitions														
*** Severe acute respiratory infection														

330 Table 4. Assessment of sources for case definition and testing criteria across the COVID-19

331 pandemic's 25 highest burden countries, current as of 1 January 2021.

Countries	Case Definition Source (Date)*	Testing Criteria Source (Date)*						
WHO	WHO ⁶ (8/7/2020)	N/A						
Argentina	Government ³⁴ (9/11/2020)	Government ³⁵ (9/23/2020)						
Bangladesh	Government ³⁶ (11/5/2020)	Government ³⁶ (11/5/2020)						
Brazil	Government ³⁷ (8/5/2020)	Government ³⁷ (8/5/2020)						
Chile	Government ³⁸ (10/1/2020)	Government ³⁹ (11/18/2020)***						
Colombia	Government ¹⁷ (10/19/2020)	Government ⁴⁰ (10/2020)						
France	ECDC ⁴¹ (12/3/2020)	Government ⁴² (10/19/2020)***						
Germany	ECDC ⁴¹ (12/3/2020)	Government ⁴³ (12/16/2020)						
India	Government ⁴⁴ (7/3/2020)	Government ⁴⁵ (9/4/2020)						
Indonesia	Government ⁴⁶ (7/13/2020)	Government ⁴⁷ (1/1/2021)**						
Iran	CDC contact ⁴⁸ (9/29/2020)*	CDC contact ⁴⁸ (9/29/2020)*						
Iraq	CDC contact ⁴⁹ (10/2/2020)*	CDC contact ⁴⁹ (10/2/2020)*						
Israel	CDC contact ⁵⁰ (10/7/2020)*	Government ⁵¹ (12/17/2020)						
Italy	ECDC ⁴¹ (12/3/2020)	Government ⁵² 10/23/2020)						
Mexico	Government ^{53,54} (8/25/2020)	Government ⁵⁵ (11/11/2020)						
Pakistan	Government ⁵⁶ (3/27/2020)	Government ^{57,58} (12/2/2020)						
Peru	Government ⁵⁹ (7/10/2020)	Government ⁶⁰ (9/30/2020)						
Philippines	Government ⁶¹ (11/25/2020)	Government ⁶² (7/6/2020)						
Russia	Government ⁶³ (10/26/2020)	Government ⁶⁴ (1/1/2021)**						
Saudi Arabia	Government ⁶⁵ (10/2020)	Government ⁶⁵ (10/2020)						
South Africa	Government ⁶⁶ (8/18/2020)	Government ⁶⁷ (9/16/2020)						
Spain	Government ⁶⁸ (12/18/2020)	Government ⁶⁸ (12/18/2020)						
Turkey	Government ⁶⁹ (12/7/2020)	Government ⁶⁹ (12/7/2020)						
Ukraine	Government ⁷⁰ (3/28/2020)	Government ⁷¹ (1/1/2021)**						
UK	Government ⁷² (9/28/2020)	Government ⁷³ (1/1/2021)**						
USA	Government ¹⁶ (8/5/2020)	Government ⁸ (10/21/2020)						

* Date of U.S. Centers for Disease Control and Prevention (CDC) contact communication **Date the source website was last verified in absence of website update date

*** Date the website was last updated

335 **References**

- 1 Zhu N, Zhang D, Wang W, *et al.* A Novel Coronavirus from Patients with Pneumonia in
 China, 2019. *N Engl J Med* 2020; **382**: 727–33.
- National Health Commission of the People's Republic of China. Update on the novel
 coronavirus pneumonia outbreak. http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml.
- World Health Organization. Statement on the second meeting of the International Health
 Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus
 (2019-nCoV). https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak of-novel-coronavirus-(2019-ncov).
- World Health Organization. Global Surveillance for human infection with novel coronavirus
 (2019-nCoV): interim guidance, 31 January 2020. 2020.
- 347 https://apps.who.int/iris/handle/10665/330857 (accessed Dec 13, 2020).
- World Health Organization. Global surveillance for COVID-19 caused by human infection
 with COVID-19 virus: interim guidance, 20 March 2020. 2020.
- 350 https://apps.who.int/iris/handle/10665/331506 (accessed Dec 13, 2020).
- World Health Organization. Public health surveillance for COVID-19: interim guidance, 7
 August 2020. 2020. https://apps.who.int/iris/handle/10665/333752 (accessed Dec 13, 2020).
- Koh D, Cunningham AC. Counting Coronavirus Disease-2019 (COVID-19) Cases: Case
 Definitions, Screened Populations and Testing Techniques Matter. 2020; 49: 5.
- 355 8 Overview of Testing for SARS-CoV-2 (COVID-19). 2020; published online Oct 21.
 https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html.
- Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity A Strategy for
 Containment. *N Engl J Med* 2020; **383**: e120.
- 10Preparedness and vulnerability of African countries against importations of COVID-19: a
 modelling study The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140 6736(20)30411-6/fulltext (accessed Dec 16, 2020).
- 11 Cheng MP, Papenburg J, Desjardins M, *et al.* Diagnostic Testing for Severe Acute
 Respiratory Syndrome–Related Coronavirus 2. *Ann Intern Med* 2020; **172**: 726–34.
- 12 Atsawarungruangkit A, Yuan J, Kodama T, *et al.* Evolving global and national criteria for
 identifying a suspected case of COVID-19. *J Int Med Res* 2020; **48**: 0300060520938943.
- 13Peralta-Santos A. Assessment of COVID-19 surveillance case definitions and data reporting
 in the European Union.; : 7.

368 369 370	14Tsang TK, Wu P, Lin Y, Lau EHY, Leung GM, Cowling BJ. Effect of changing case definitions for COVID-19 on the epidemic curve and transmission parameters in mainland China: a modelling study. <i>Lancet Public Health</i> 2020; 5 : e289–96.
371 372	15WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int (accessed Jan 29, 2021).
373 374 375	16Coronavirus Disease 2019 (COVID-19) 2020 Interim Case Definition, Approved August 5, 2020. 2020; published online Aug 5. https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/08/05/ (accessed Oct 13, 2020).
376 377 378	17Por el cual se optimiza el Programa de Pruebas, Rastreo y Aislamiento Selectivo Sostenible - PRASS, para el monitoreo y seguimiento de casos y contactos de COVID - 19 en Colombia. Colombia: Republic of Colombia, 2020.
379 380 381	18World Health Organization. Global surveillance for COVID-19 disease caused by human infection with novel coronavirus (COVID-19): interim guidance, 27 February 2020. 2020. https://apps.who.int/iris/handle/10665/331231 (accessed Dec 13, 2020).
382 383	19 Teutsch S. Considerations in Planning a Surveillance System. In: Principles & Practice of Public Health Surveillance. Oxford: Oxford University Press, 2010: 18–30.
384 385 386	20 Timen A, van Doornum GJJ, Schutten M, <i>et al.</i> Public health implications of using various case definitions in The Netherlands during the worldwide SARS outbreak. <i>Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis</i> 2006; 12 : 1214–20.
387 388 389 390	21 Wu P, Hao X, Lau EHY, <i>et al.</i> Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. <i>Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull</i> 2020; 25 . DOI:10.2807/1560-7917.ES.2020.25.3.2000044.
391 392 393	22Dawson P, Rabold EM, Laws RL, <i>et al.</i> Loss of Taste and Smell as Distinguishing Symptoms of Coronavirus Disease 2019. <i>Clin Infect Dis</i> 2020; published online June 21. DOI:10.1093/cid/ciaa799.
394 395	23 Haehner A, Draf J, Dräger S, de With K, Hummel T. Predictive Value of Sudden Olfactory Loss in the Diagnosis of COVID-19. <i>ORL</i> 2020; 82 : 175–80.
396 397	24Roland LT, Gurrola JG, Loftus PA, Cheung SW, Chang JL. Smell and taste symptom-based predictive model for COVID-19 diagnosis. <i>Int Forum Allergy Rhinol</i> 2020; 10 : 832–8.
398 399 400	25 Yamamoto-Moreno JA, Pineda-Aguilar C, Ruiz-Pérez S, Gortarez-Quintana GL, Ruiz-Dorado MA. Effectiveness of COVID-19 case definition in identifying SARS-CoV-2 infection in northern Mexico. <i>Popul Med</i> 2020; 2 : 1–8.
401 402 403	26Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. 2020; published online March 19. https://www.who.int/publications/i/item/10665-331501 (accessed Dec 18, 2020).

- 404 27 CDC. Information for Laboratories about Coronavirus (COVID-19). Cent. Dis. Control Prev.
- 405 2020; published online Feb 11. https://www.cdc.gov/coronavirus/2019-
- 406 ncov/lab/resources/antigen-tests-guidelines.html (accessed Dec 18, 2020).
- 28Krajewski R, Gołębiowska J, Makuch S, Mazur G, Agrawal S. Update on serologic testing in
 COVID-19. *Clin Chim Acta* 2020; **510**: 746–50.
- 29 Hanson KE, Caliendo AM, Arias CA, *et al.* Infectious Diseases Society of America
 Guidelines on the Diagnosis of COVID-19. 2020; : 70.
- 411 30McArthur L, Sakthivel D, Ataide R, Chan F, Richards JS, Narh CA. Review of Burden,
- 412 Clinical Definitions, and Management of COVID-19 Cases. *Am J Trop Med Hyg* 2020; 103:
 413 625–38.
- 414 31 Interim guidelines for detecting cases of reinfection by SARS-CoV-2 PAHO/WHO | Pan
- 415 American Health Organization. https://www.paho.org/en/documents/interim-guidelines-416 detecting-cases-reinfection-sars-cov-2 (accessed Dec 18, 2020).
- 417 32Reinfection with SARS-CoV: considerations for public health response. 2020; published
- 418 online Sept 21. https://www.ecdc.europa.eu/sites/default/files/documents/Re-infection-and 419 viral-shedding-threat-assessment-brief.pdf (accessed Dec 18, 2020).
- 33WHO | SARS-CoV-2 Variants. WHO. http://www.who.int/csr/don/31-december-2020-sars cov2-variants/en/ (accessed Jan 29, 2021).
- 422 34Definición de caso. 2020; published online Sept 11.
- 423 https://www.argentina.gob.ar/salud/coronavirus-COVID-19/definicion-de-caso (accessed Jan
 424 4, 2020).
- 425 35Consenso sobre el uso de pruebas diagnósticas para SARS-CoV-2. Argentina, 2020.
- 426 36Ferdousi S. National Guidelines of Clincial Management of Coronavirus Disease 2019
 427 (Covid-19). Government of the People's Republic of Bangladesh, 2020.
- 428 37 Guia de Vigilância Epidemiológica Emergência de Saúde Pública de Importância Nacional
 429 pela Doença pelo Coronavírus 2019. Government of Brazil, 2020.
- 430 38 Actualización de definición de caso sospechoso, confirmado y probable para vigilancia
 431 epidemiológica ante pandemia de COVID-19. Government of Chile, 2020
- 432 https://www.minsal.cl/wp-content/uploads/2020/10/201006-Definici%C3%B3n-de-caso-
- 433 sospechoso.pdf (accessed Jan 4, 2020).
- 434 39Plan de Acción por Coronavirus. 2020; published online Nov 18.
 435 https://www.gob.cl/coronavirus/plandeaccion#salud/ (accessed Nov 30, 2020).
- 436 40 ABECÉ Programa de Pruebas, Rastreo y Aislamiento Selectivo Sostenible PRASS. 2020;
 437 published online Oct.

- https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/VSP/abece prass.pdf.
- 440 41Case definition for coronavirus disease 2019 (COVID-19), as of 29 May 2020. 2020;
- 441 published online May 29. https://www.ecdc.europa.eu/en/covid-19/surveillance/case-
- 442 definition (accessed Sept 16, 2020).
- 443 42Dépistage□: les réponses à vos questions. 2020; published online Oct 19. https://solidarites444 sante.gouv.fr/soins-et-maladies/maladies/maladies-infectieuses/coronavirus/tout-savoir-sur-la445 covid-19/article/depistage-les-reponses-a-vos-questions (accessed Dec 3, 2020).
- 446 43Die nationale Teststrategie. 2020; published online Dec 16.
- 447 https://www.zusammengegencorona.de/informieren/die-nationale-teststrategie/ (accessed Jan
 448 5, 2020).
- 449 44Clinical Management Protocol: COVID-19. Government of India, 2020.
- 450 45 Advisory on Strategy for COVID-19 Testing in India. 2020; published online Sept 4.
- 451 https://www.mohfw.gov.in/pdf/AdvisoryonstrategyforCOVID19TestinginIndia.pdf (accessed
 452 Nov 25, 2020).
- 453 46Pedoman Pencegahan Dan Pengendalian Coronavirus Disease 2019 (COVID-19). Republic of
 454 Indonesia, 2020.
- 455 47 Tanya Jawab. 2020. https://covid19.go.id/tanya-jawab?page=2 (accessed Dec 3, 2020).
- 456 48Farag N. Case definitions and testing criteria question. 2020; published online Sept 29.
- 457 49Majeed YY. Seeking COVID-19 surveillance case definitions and testing criteria. 2020;
 458 published online Oct 2.
- 459 50Burke H. Case definitions and testing criteria question. 2020; published online Oct 7.
- 460 51 Testing for COVID-19. 2020; published online Dec 17.
- 461 https://www.gov.il/en/Departments/General/corona-tests (accessed Jan 4, 2020).
- 465 53Dirección General de Epidemiología. Actualización de la Definición Operacional de Caso
- 466 Sospechoso de Enfermedad Respiratoria Viral. Government of Mexico, 2020
- 467 https://www.gob.mx/cms/uploads/attachment/file/573732/Comunicado_Oficial_DOC_sospec
- 468 hoso_ERV_240820.pdf (accessed Sept 16, 2020).
- 469 54Bastidas DrMA. Lineamiento Estandarizado Para La Vigilancia Epidemiológica Y Por
- 470 Laboratorio De La Enfermedad Respiratoria Viral. Government of Mexico, 2020
- 471 https://coronavirus.gob.mx/wp-

- 472 content/uploads/2020/09/Lineamiento_VE_y_Lab_Enf_Viral_Ago-2020.pdf (accessed Jan 4, 2020).
- 474 55Zegarra JLA. Comunicado emergente sobre el uso de pruebas para la detección de antígeno
 475 SARS-CoV-2 en México. Government of Mexico, 2020 https://coronavirus.gob.mx/wp476 content/uploads/2020/11/Prueba entigenica. COVID: 11Nev2020 pdf (accessed Dec 3: 2020)
- 476 content/uploads/2020/11/Prueba_antigenica_COVID_11Nov2020.pdf (accessed Dec 3, 2020).
- 56Case Definition for COVID-19. Islamabad: Islamic Republic of Pakistan, 2020
 https://www.nih.org.pk/wp-content/uploads/2020/03/Case-Definition-for-COVID-19.pdf
 (accessed Nov 27, 2020).
- 480 57 National Testing Guidelines Real-Time Polymerase Chain Reaction (RT-PCR) Diagnostic
 481 Test. Islamic Republic of Pakistan, 2020.
- 482 58 Ministry of National Health Services. Testing Strategy Incorporating COVID-19 Antigen
- 483 Detection Rapid Diagnostic Tests (Ag-RDT). Islamic Republic of Pakistan, 2020
- 484 https://storage.covid.gov.pk/new_guidelines/02December2020_20201202_TESTING_STRA
- 485 TEGY_INCORPORATING_COVID-
- 486 19_ANTIGEN_DETECTION_RAPID_DIAGNOSTIC_TESTS_(Ag-RDT)_5302.pdf
 487 (accessed Jan 5, 2020).
- 488 59Alerta epidemiológica ante riesgo de intensificación de la transmisión comunitaria de
- 489 COVID-19 en el periodo post cuarentena, en el Perú. Government of Peru, 2020
- 490 https://www.dge.gob.pe/portal/docs/alertas/2020/AE019.pdf (accessed Jan 4, 2020).
- 491 60 Alerta epidemiológica para la aplicación de pruebas diagnósticas en casos de COVID-19 en el
- 492 Perú. Government of Peru https://www.dge.gob.pe/portalnuevo/publicaciones/alertas493 epidemiologicas/ (accessed Sept 30, 2020).
- 61 Further Amendment to Administrative Order No. 2020-0013 dated 09 April 2020 entitled,
 "Revised Administrative Order No. 2020-0012, 'Guidelines for the Implementation for the
 Inclusion of the Coronavirus Disease 2019 (COVID-19) in the list of Notifiable Diseases for
 Mandatory Reporting to the Department of Health' dated March 17, 2020." Republic of the
- 498 Phillipines, 2020 https://doh.gov.ph/sites/default/files/health-update/ao2020-0013-B.pdf
- 499 (accessed Jan 4, 2020).
- 62 Duque III FT, III FTD. Amendment to Department Memorandum No. 2020-0258 entitled
 Updated Interim Guidelines on Expanded Testing for COVID-19. Republic of the Philippines,
 2020 https://www.doh.gov.ph/sites/default/files/health-update/dm2020-0258-A.pdf.
- 63 Vremennyye Metodicheskiye Rekomendatsii Profilaktika, Diagnostika I Lecheniye Novoy
 Koronavirusnoy Infektsii (COVID-19). Russian Federation, 2020.
- 505 64 Chasto Zadavayemyye Voprosy. 2020. https://xn--80aesfpebagmfblc0a.xn--p1ai/faq/?tags=39
 506 (accessed Nov 30, 2020).
- 507 65COVID-19 Coronavirus Disease Guidelines. the Kingdom of Saudi Arabia, 2020.

- 66Coronavirus disease 2019 (COVID-19) caused by a Novel Coronavirus (SARS-CoV-2).
 Republic of South Africa, 2020.
- 67 Ramaphosa C. Statement by President Cyril Ramaphosa on Progress in the National Effort to
 Contain the COVID-19 Pandemic. 2020; published online Sept 16.
- 512 https://sacoronavirus.co.za/2020/09/16/statement-by-president-cyril-ramaphosa-on-progress-
- 513 in-the-national-effort-to-contain-the-covid-19-pandemic-3/.
- 68Estrategia de Detección Precoz, Vigilancia y Control de Covid-19. Government of Spain,
 2020.
- 516 69T.R. Ministry of Health. COVID-19 (SARS-CoV-2 Enfeksiyonu) Genel Bilgiler,
- 517 Epidemioloji Ve Tani. Ankara: Republic of Turkey, 2020.
- 70 Informatsiyni materialy na osnovi Standartiv medychnoyi dopomohy Koronavirusna khvoroba
 COVID-19. 2020; published online June 16.
- 520 71 Coronavirus in Ukraine. https://covid19.gov.ua/en (accessed Dec 8, 2020).
- 521 72COVID-19: investigation and initial clinical management of possible cases. 2020; published
- 522 online Oct 2. https://www.gov.uk/government/publications/wuhan-novel-coronavirus-initial-
- 523 investigation-of-possible-cases/investigation-and-initial-clinical-management-of-possible-
- 524 cases-of-wuhan-novel-coronavirus-wn-cov-infection (accessed Nov 25, 2020).
- 525 73 Getting tested for coronavirus (COVID-19). https://www.gov.uk/getting-tested-for-526 coronavirus (accessed Nov 30, 2020).
- 527
- 528

529 Appendix 1. Suspect Definitions

Country	Definition
WHO	1. A person who meets the clinical AND epidemiological criteria: Clinical Criteria: Acute onset of fever AND cough; OR Acute onset of any three or more of the following signs or symptoms: fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, anorexia/nausea/vomiting, diarrhea, altered mental status Epidemiological Criteria: Residing or working in an area with high risk of transmission of virus: closed residential settings
Iraq†	humanitarian settings such as camp and camp-like settings for displaced persons; anytime within the 14 days prior to symptom onset: OR Residing or travel to an area with community transmission anytime within the 14 days prior to symptom
Bangladesh†	onset; OR Working in any health care setting, including within health facilities or within the community; anytime within the 14
Philippines†	2. A patient with severe acute respiratory illness (SARI: acute respiratory infection with history of fever or measured fever of \geq 38 C°; and cough; with onset within the last 10 days; and requires hospitalization)
India	 A patient with acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath), AND a history of travel to or residence in a location reporting community transmission of COVID-19 disease during the 14 days prior to symptom onset. A patient with any acute respiratory illness AND having been in contact with a confirmed or probable COVID-19 case (see definition of contact) in the last 14 days prior to symptom onset.
Pakistan	 A patient with severe acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g. cough, shortness of breath; AND requiring hospitalization) AND in the absence of an alternative diagnosis that fully explains the clinical presentation.
USA	Meets supportive laboratory evidence with no prior history of being a confirmed or probable case. Supportive Lab evidence: Detection of specific antibody in serum, plasma, or whole blood. Detection of specific antigen by immunocytochemistry in an autopsy specimen
Italy*‡	Any person meeting clinical criteria: at least one of the following symptoms: cough, fever, shortness of breath, sudden onset
Germany*‡	of anosmia, ageusia or dysgeusia. Additional less specific symptoms may include headache, chills, muscle pain, fatigue,
France*‡	
Brazil	 Individual with acute respiratory condition, characterized by at least two (2) of the following signs and symptoms: fever (even if referred), chills, sore throat, headache, cough, runny nose, olfactory disorders or taste disorders. In children in addition to the previous items, nasal obstruction is also considered, in the absence of another specific diagnosis. In the elderly specific aggravation criteria such as syncope, mental confusion, excessive sleepiness, irritability and inappetence should also be considered. If COVID-19 is suspected, fever may be absent and gastrointestinal symptoms (diarrhea) may be present. Individual with Influenza like illness who has: dyspnea / respiratory discomfort Or persistent pressure in the chest Or O₂ saturation less than 95% in room air Or bluish color of the lips or face. In children in addition to the previous items, observe
Russia	Clinical manifestations of acute respiratory infection (ARI) (temperature above 37.5 ° C and one or more of the following: cough - dry or with scanty sputum, shortness of breath, feeling of congestion in the chest, satiety blood oxygen according to pulse oximetry (SpO2) \leq 95%, sore throat, nasal congestion or mild rhinorrhea, impaired or loss of smell (hyposmia or anosmia), loss of taste (dysgeusia), conjunctivitis, weakness, muscle pain, headache, vomiting, diarrhea, skin rash) in the absence of other known causes, which explain the clinical picture regardless of the epidemiological anamnesis.
Colombia	 Person with exposure due to having been in a place with community transmission or endemic or outbreak or to probable cases, and with respiratory OR non-respiratory clinical manifestations of COVID-19, of any severity, clinical laboratory findings or radiological, belonging to groups of risk factors or vulnerability. Also asymptomatic individuals with exposure to probable or confirmed COVID-19 cases. Respiratory clinical manifestations: fever greater than 38°C, cough, fatigue, expectoration, shortness of breath / dyspnea, sore throat, rhinorrhea, Sp02 <93%. Non-respiratory clinical manifestations: anosmia, hyposmia, ageusia, dysgeusia, diarrhea, anorexia, nausea and vomiting, abdominal pain or discomfort, acute conjunctivitis, seizures, vertigo, headache, myalgia, skeletal muscle injuries, altered consciousness, acute cerebrovascular disease, ataxia, seizures, meningoencephalitis, Guillain-Barre syndrome, mental status disorders, hepatic compromise due to elevated aminotransferases, erythematous rash, hive rash, vesicles, acral ischemia, unilateral transient livedo reticularis, acute cardiac injury, heart failure arrhythmia, shock, acute myocarditis, chest tightness, acute kidney injury, urinary symptoms / cystitis, coagulation disorders, thrombotic events, antiphospholipid antibodies, hearing loss or hearing discomfort Clinical Laboratory and Radiological findings: Laboratory and non-etiological clinical diagnostic tests: Albumin Decrease (81%), CRP increase (79%) (MIS-C 94%), LDH increase (37%), Leukopenia (28%, 25%), Leukoztosis (81.3%), Neutrophilia (MIS-C 83%), Thrombocytopenia (13%, 16.4-32.3%), Increase in D-dimer, Ferritin, Decrease in T3 and T 4 Troponin T (MIS-C 68%), pro BNP (MIS-C 77%). Pulmonary radiological findings Bilateral commitment (81%), Consolidation (73.5%), Ground Glass Opacity (73.5%), Abnormal echocardiogram (MIS-C 59%, 63%). Factors of Vulnerability: Health workers, Workers who serve in high volumes of public work in social protection, workers with hi
Peru	signs / symptoms: General discomfort, Fever, Headache, Difficulty breathing, Nasal congestion.

Argentina	 Anyone (of any age) who has two or more of the following symptoms: Fever (37.5 ° C or more), Cough, Odynophagia, Shortness of breath, Headache, Myalgia, Diarrhea / vomiting, No other etiology that fully explains the clinical presentation. This criterion includes any severe acute respiratory infection Sudden loss of taste or smell, in the absence of any other identified cause Anyone who is a health worker, resides or works in closed or long-term institutions, is essential personnel, lives in popular neighborhoods or native towns, or had close contact of confirmed COVID-19 case, that within 14 days of contact AND has 1 or more of these symptoms: fever (37.5 ° C or higher), cough, odynophagia, shortness of breath, sudden loss of taste or smell.
Spain	Anyone with a clinical picture of acute respiratory infection of onset sudden of any severity that occurs, among others, with fever, cough or feeling of shortness of breath. Other symptoms such as odynophagia, anosmia, ageusia, muscle pain, diarrhea, chest pain or headache, among others may also be considered symptoms of suspected SARS-CoV-2 infection according to clinical judgment.
Mexico	Person of any age who has had at least one of the following signs and symptoms in the last 10 days: cough, fever, dyspnea (serious condition) or headache. In children under five years of age, irritability can replace headache. Accompanied by at least one of the following minor signs or symptoms: Myalgia, Arthralgias, Odynophagia, Chills, chest pain, Rhinorrhea, Anosmia, dysgeusia, Conjunctivitis.
South Africa	Any person presenting with an acute (≤10days) respiratory tract infection or other clinical illness compatible with COVID-19, or an asymptomatic person who is a close contact a of a confirmed case. Symptoms include ANY of the following respiratory symptoms: cough, sore throat, shortness of breath, anosmia (loss of sense of smell) or dysgeusia (alteration of the sense of taste), with or without other symptoms (which may include fever, weakness, myalgia, or diarrhea)
United Kingdom*	New continuous cough or temperature ≥37.8°C or loss of, or change in, normal sense of smell (anosmia) or taste (ageusia)
Iran	 Acute onset of fever OR Acute onset of ILI/ARI symptoms / nausea and vomiting AND epidemiological criteria (residing/working/travel to high-risk settings or community transmission or health facilities within 14 days) SARI
Chile	 Patient presenting an acute picture with at least two of the symptoms compatible with Covid-19: fever (37.8 ° C or higher), cough, dyspnea, chest pain, odynophagia, myalgia, chills, headache, diarrhea, or sudden loss or decrease of smell (anosmia or hyposmia) or taste (ageusia or dysgeusia) Patient with severe acute respiratory infection (requiring hospitalization).
Saudi Arabia	 Patient with acute respiratory illness (sudden onset of at least one of the following: fever (measured or by history), cough, or shortness of breath Patient with sudden onset of at least one of the following: headache, sore throat, rhinorrhea, nausea, diarrhea or loss of smell or taste. AND in the 14 days prior to symptom onset, met at least one of the following criteria Had contact with a confirmed COVID-19 case Or Working in or attended a healthcare facility where patients with confirmed COVID-19 were admitted. Any admitted Adult patient with unexplained sever acute respiratory illness (SARI), either Community Acquired Pneumonia (CAP) or Hospital Acquired Pneumonia (HAP)
Turkey*	 At least one of the following signs and symptoms: fever, cough, shortness of breath, sore throat, headache, muscle aches, loss of taste and smell, diarrhea AND The clinical picture cannot be explained by another cause / disease AND one of the following within 14 days before the onset of symptoms: he or close contact has history of being in a high-risk area for the disease or he has confirmed contact with a COVID-19 case. At least one of the signs and symptoms of fever and SARI (cough and respiratory distress), requiring hospitalization and the clinical picture cannot be explained by another cause / disease. SARI: The need for hospitalization due to fever, cough and dyspnea, tachypnea, hypoxemia, hypotension, diffuse radiological findings on lung imaging and change in consciousness in a patient with acute respiratory tract infection that developed in the last 14 days Combination of at least two of the following signs and symptoms: fever, cough, shortness of breath, sore throat, headache, muscle aches, loss of taste and smell or diarrhea, and this situation cannot be explained by another cause / disease.
Indonesia	 A person who has one of the following criteria: People with Acute Respiratory Infections (ARI) (namely fever (≥38oC) or a history of fever; and accompanied by any of the symptoms / signs of respiratory disease such as: cough / shortness of breath / sore throat / runny nose / pneumonia from mild to severe) * AND in the last 14 days before symptoms appeared had a history travel or live in a country / territory of Indonesia reporting local transmissions People with any of the symptoms / signs of ARI AND in the last 14 days before symptoms develop had a history of contact with a confirmed / probable COVID-19 case. People with severe ARD / severe pneumonia requiring hospitalization AND no other cause based on a convincing clinical picture.
Israel	Israel does not have official surveillance case definitions; individuals are considered suspect based on contact with confirmed cases determined by digital surveillance of cellphones
Ukraine	 A patient with acute respiratory illness (sudden onset, fever, and at least one of the following symptoms: cough or difficulty breathing), regardless of the need for hospitalization, and who 14 days before the onset of symptoms meets at least one of the following epidemiological criteria: Had contact with a confirmed or probable case of COVID-19 or visited or resided in a country / region with local transmission of the virus in the community according to WHO situation reports. Patient with severe acute respiratory disease (body temperature ≥ 38°C and at least one of the following symptoms: cough or difficulty breathing), and the need for hospitalization and the absence of other reasons that fully explain the clinical picture.

* These countries use a "Possible" case definition in place of a "Suspected" case definition †World Health Organization Definition

530

[‡] European Centres for Disease Control and Prevention Definition

532 Appendix 2. Probable Definitions

Country	Definition
WHO Definition	 A patient who meets clinical criteria above AND is a contact of a probable or confirmed case, or epidemiologically linked to a cluster with at least one confirmed case A suspect case with chest imaging showing findings suggestive of COVID-19 disease Typical chest imaging findings suggestive of COVID-19 include the following chest radiography: hazy opacities, often rounded in morphology, with peripheral and lower lung distribution; chest CT: multiple bilateral ground glass opacities, often rounded in morphology, with peripheral and lower lung distribution; lung ultrasound: thickened pleural lines, B lines (multifocal, discrete, or confluent), consolidative patterns with or without air bronchograms.
Iraq†	3. A person with recent onset of anosmia (loss of smell) or ageusia (loss of taste) in the absence of any other identified
Bangladesh†	Cause
Philippines†	or confirmed case or epidemiologically linked to a cluster with at least one confirmed case.
India Pakistan	 A suspect case for whom testing for the COVID-19 virus is inconclusive. A suspect case for whom testing could not be performed for any reason.
USA	 Meets clinical criteria AND epidemiologic evidence with no confirmatory laboratory testing performed for COVID-19 Meets presumptive laboratory evidence (Detection of SARS-CoV-2 by antigen test in a respiratory specimen) Meets vital records criteria with no confirmatory laboratory evidence Clinical Criteria: At least two of the following symptoms: fever (measured or subjective), chills, rigors, myalgia, headache, sore throat, nausea or vomiting, diarrhea, fatigue, congestion or runny nose OR At least one of the following symptoms: cough, shortness of breath, difficulty breathing, new olfactory disorder, new taste disorder OR Severe respiratory illness with at least one of the following: Clinical or radiographic evidence of pneumonia, Acute respiratory distress syndrome (ARDS). Epi Criteria: One or more of the following exposures in the prior 14 days: Close contact with a confirmed or probable case of COVID-19 disease; OR Member of a risk cohort as defined by public health authorities during an outbreak.
Italy‡	Any person meeting clinical criteria (at least one of the following symptoms: cough, fever, shortness of breath, sudden
Germany‡	onset of anosmia, ageusia or dysgeusia) with Epi link (Close contact with confirmed case within 14 days prior to onset or baying been a resident or staff in an institution with ongoing transmission, within 14 days prior to onset) OR Any person
France‡	meeting diagnostic criteria (Radiological evidence showing lesions compatible with COVID-19)
Brazil	No Probable case definition
Russia	Same as Suspected case AND at least one of the epidemiological signs is present: Return from a foreign trip 14 days before the onset of symptoms; Having close contact in the last 14 days with a person under monitoring for COVID-19, which subsequently fell ill; Having close contact in the last 14 days with a person who laboratory confirmed diagnosis of COVID-19; Availability of professional contacts with persons who have been identified a suspected or confirmed case of COVID-19.
Colombia	Person with any type of individual or multiple exposure to confirmed cases and with respiratory or non-respiratory clinical manifestations of COVID-19, of any severity and clinical or radiological laboratory findings. It also includes the person with doubtful etiological laboratory results (RT-PCR) or laboratory testing is not feasible for some reason Respiratory clinical manifestations: fever greater than 38°C, cough ,fatigue, expectoration, shortness of breath / dyspnea, sore throat, rhinorrhea, Sp02 <93% Non-respiratory clinical manifestations: anosmia, hyposmia, ageusia, dysgeusia, diarrhea, anorexia, nausea and vomiting, abdominal pain or discomfort, acute conjunctivitis, seizures, vertigo, headache, myalgia, skeletal muscle injuries, altered consciousness, acute cerebrovascular disease, ataxia, seizures, meningoencephalitis, Guillain-Barre syndrome, mental status disorders, hepatic compromise due to elevated aminotransferases, erythematous rash, hive rash, vesicles, acral ischemia, unilateral transient livedo reticularis, acute cardiac injury, heart failure arrhythmia, shock, acute myocarditis, chest tightness, acute kidney injury, urinary symptoms / cystitis, coagulation disorders, thrombotic events, antiphospholipid antibodies, hearing loss or hearing discomfort
Argenting	No Probable case definition
Spain	 Person with severe acute respiratory infection with clinical and radiological symptoms compatible with COVID-19 and negative diagnostic test results, or suspected cases with inconclusive diagnostic test. Cases with high clinical-epidemiological suspicion with repeatedly negative diagnostic test (at least one PCR) and positive serology for SARS-CoV-2 performed by high-throughput serological techniques.
Mexico	No Probable case definition
South Africa United Kingdom	No Probable case definition No Probable case definition
Iran	 Suspect case AND close contact with probable/confirmed case Suspect case AND positive imaging Acute onset of Anosmia/ageusia without identified cause Death of a Suspect Case

Chile	 Probable case by laboratory result: patient who meets the definition of a suspected case in which the PCR result is indeterminate or has a positive antigenic test for SARS-CoV-2. Probable case due to epidemiological link: person who has been in close contact with a confirmed case and develops fever (axillary temperature ~ 37.8) or at least two symptoms compatible with COVID-19 within 14 days of contact. The probable case due to an epidemiological link does not require an RT-PCR test for SARS-CoV-2. If for any reason, a probable case is carried out a confirmatory examination and it is positive, it will be considered as a confirmed case. On the contrary, if the result is negative or indeterminate, it will continue to be considered a probable case. Probable case by imaging: suspicious case with negative RT-PCR result for SARS-CoV-2 but with a chest CT scan with characteristic images of COVID-19 according to the radiological report. 	
	4. Probable case due to symptoms: person with sudden and complete loss of smell (anosmia) or taste (ageusia) without an explanation.	
Saudi Arabia	No Probable case definition	
Turkey	No Probable case definition	
Philippines	 Suspect case whose testing for COVID-19 is inconclusive Suspect who tested positive for COVID-19 but whose test was not conducted in a national or subnational reference laboratory or officially accredited laboratory for COVID-19 confirmatory testing Suspect case who died without undergoing any confirmatory testing 	
Indonesia	 Suspected cases with SARI Died with a convincing clinical picture of COVID-19 AND no RT-PCR laboratory results 	
Israel	Israel does not have official surveillance case definitions; individuals are considered suspect based on contact with confirmed cases determined by digital surveillance of cellphones	
	A suspected case for whom lab testing cannot be unambiguously interpreted	
Ukraine		

†World Health Organization definition

‡ European Centres for Disease Control and Prevention Definition

533

535 Appendix 3. Confirmed Definitions

Country	Definition
WHO	
Iraq†	A person with laboratory confirmation of 2019-nCoV infection irrespective of clinical signs and symptoms
Bandladesht	
Philippines†	 Any individual, irrespective of presence or absence of clinical signs and symptoms, who was laboratory confirmed for COVID- 19 in a test conducted at the national reference laboratory, a subnational reference laboratory, and/or DOH-licensed COVID-19 testing laboratory Any suspect or probable COVID-19 cases, who tested positive using antigen tests in areas without breaks and/or in remote settings where RT-PCR is not immediately available; provided that the antigen tests satisfy the recommended minimum regulatory, technical and operational specifications set by the Health Technology Assessment
India	
Pakistan	A person with laboratory confirmation of 2019-nCoV infection, irrespective of clinical signs and symptoms.
USA	Meets confirmatory laboratory evidence (Detection of severe acute respiratory syndrome coronavirus 2 ribonucleic acid (SARS-CoV-2 RNA) in a clinical specimen using a molecular amplification detection test)
Italy‡	
Germany‡	Any person meeting laboratory criteria (Detection of SARS-CoV-2 nucleic acid or antigen in a clinical specimen)
France [‡]	
	1. Case of ILI or SARI with clinical confirmation associated with anosmia (olfactory dysfunction) OR ageusia (gustatory
	dysfunction) without any other previous cause.
	2. Case of ILI or SARI with history of close of nome contact, in the 14 days prior to appearance of signs and symptoms with
Brazil	 confirmed case. 3. Case of ILI or SARI or death due to SARS that could not be confirmed by laboratory criteria AND that presents at least one (1) of the following tomographic changes: peripheral, bilateral, frosted glass opacity, with or without consolidation or visible intralobular lines ("paving"), Or Multifocal matte glass opacity with rounded morphology with or without consolidation or visible intralobular lines ("paving"), Or multifocal matte glass opacity with rounded morphology with or without consolidation or visible intralobular lines ("paving"), Or reverse halo sign or other findings of organizing pneumonia (seen later in the disease). 4. Case of ILI or SARI with test of positive result for SARS-CoV-2 performed by the RT-PCR method in real time. Or REAGENT result for IgM, IgA and / or IgG * performed by the following methods: Immunoenzymatic assay (Enzyme-Linked Immunosorbent Assay - ELISA); Immunochromatography (rapid test) for antibody detection; Electrochemiluminescence Immunoassay (ECLIA), Or Antigen Search: reagent result for SARS-CoV-2 by the Immunochromatography method for antigen detection . 5. Asymptomatic individuals with one of the following results: positive result for SARS-CoV-2 performed by the RT-PCR method in real time. Or immunological reagent result for IGM and / or IGA performed by the following methods: ELISA or
	Immunochromatography (rapid test) for antibody detection.
Russia	1. A positive laboratory test result for the presence of RNA SARS-CoV-2 using nucleic acid amplification techniques (NAAT) or SARS-CoV-2 antigen using immunochromatographic analysis regardless of clinical manifestations.
	Person with laboratory (RT-PCR for SARS-CoV-2 (IVIIS-C 59%, 13-69%) or Antigen detection test (alternative diagnosis, May
Colombia	change according to new evidence)) with positive results of active infection by the SARS-CoV-2 virus regardless of the presence or absence of clinical criteria, since the tests can be performed in asymptomatic, suspected or probable patients, with different prioritization.
	1. Suspected case with a positive laboratory test for COVID 19, be it a reverse transcriptase polymerase chain reaction (RT-PCR)
Peru	test in respiratory samples RT-PCR and / or a rapid IgM, IgG or IgG / IgM detection test.
	2. Asymptomatic contact with a positive laboratory test for COVID-19.
Argentina	 Confirmed by COVID-19 laboratory: any suspected cases with a detectable result for SARS-cov-2 by molecular biology tests by reverse transcriptase polymerase chain reaction (RT-PCR), by molecular biology tests by loop-mediated isothermal amplification reaction (LAMP), or SARS-cov-2 antigens by non-molecular tests. Confirmatory diagnosis in suspected cases with mild / moderate symptoms, only during the first 7 days from the onset of symptoms Confirmed by clinical / epidemiological criteria COVID-19: In the last 14 days Has been in close contact with a confirmed case OR Is part of a conglomerate of cases, with at least one case confirmed by laboratory, with no other defined diagnosis, and presenting two or more of the following symptoms: fever, cough, odynophagia, difficulty breathing, vomiting / diarrhea / headache / myalgia Any person who, in the absence of any other identified cause, begins with: Sudden loss of taste or smell
	4. Any deceased person who: Do not have a defined etiological diagnosis Has had a clinical picture compatible with COVID-19 (known by the certifying doctor or referred by third parties) Regardless of previous health status and that it has been close contact of a confirmed case or has been epidemiologically linked to a cluster of cases or to areas of sustained community transmission.
Spain	 Person who meets clinical criteria for a suspected case and with a positive diagnostic test. Asymptomatic person with positive diagnostic test with negative IgG or not performed.
Mexico	 Person who meets the operational definition of suspected case and has a diagnosis laboratory confirmed issued by InDRE. Person who meets the operational definition of a suspected case, but who has been in contact with a laboratory confirmed case within the last 14 days from the date of onset of symptoms.
South Africa	A person with laboratory confirmation of SARS-CoV-2 infection (using an RT-PCR assay), irrespective of clinical signs and symptoms.

United Kingdom	Positive COVID-19 test result
Iran	Laboratory confirmation with or without suspect or probable criteria
Chile	 Anyone who meets the definition of a suspected case in which the specific test for SARS-CoV-2 was positive (RT-PCR). Any asymptomatic person identified through an active search strategy in which the specific test for SARS-CoV-2 was positive (RT-PCR).
Saudi Arabia	A person who meets the suspected case definition with laboratory confirmation of COVID-19 infection (PCR).
Turkey	Cases in which SARS-CoV-2 is detected by molecular methods among the cases matching the possible case definition.
Indonesia	A person who has tested positive for the COVID-19 virus proven by the RT-PCR laboratory examination. Confirmation cases are divided into: Confirmation case with symptoms (symptomatic), Confirmation cases without symptoms (asymptomatic)
Israel	Positive COVID-19 test result
Ukraine	A person with a laboratory confirmed COVID-19 disease, regardless of clinical signs and symptoms.

†World Health Organization definition

‡ European Centres for Disease Control and Prevention Definition

537 Appendix 4. Country Testing Policies for Asymptomatic Individuals

Countries	Asymptomatic testing	EPI Criteria: Confirmed Contact	EPI Criteria: Healthcare employee
WHO	Yes with EPI Criteria	Yes	
Iraq	Yes with EPI Criteria	Yes	
Bangladesh	No		
Philippines	Yes		
India	Yes with EPI Criteria	Yes	Yes
Pakistan	Yes		
USA	Yes		
Italy	Yes		
Germany	Yes with EPI Criteria	Yes	Yes
France	Yes		
Brazil	Yes with EPI Criteria	Yes	Yes
Russia	Yes		
Colombia	No		
Peru	No		
Argentina	No		
Spain	Yes with EPI Criteria	Yes	Yes
Mexico	No		
South Africa	Yes with EPI Criteria	Yes	
UK	No		Yes
Iran	Yes with EPI Criteria	Yes	
Chile	Yes		
Saudi Arabia	No		Yes
Turkey	Yes with EPI Criteria	Yes	Yes
Indonesia	No		
Israel	Yes		
Ukraine	No		